What Is Repaglinide?
Repaglinide is a new type of non-sulfonylurea short-acting oral insulin secretion and hypoglycemic agent. Stimulating the release of insulin from the pancreas causes a rapid decrease in blood glucose levels, a function that depends on functional beta cells in the islets. Different from other oral insulin-promoting hypoglycemic drugs, it binds different receptors to close APT-dependent potassium channels in -cell membranes, depolarizes -cells, opens calcium channels, and increases calcium influx. Induces insulin secretion from beta cells. This product promotes insulin secretion faster than sulfonamides.
Basic Information
- Chinese name
- Reglinide
- Foreign name
- Repaglinide
- Product name
- Novo Dragon
- Specifications
- 30 tablets per box (1.0mg, 2.0mg)
- Package
- Aluminum foil bubble eye packaging
- CAS
- 135062-02-1
- Molecular formula
- C27H36N2O4
- Molecular weight
- 452.5857
- Use
- Used as a hypoglycemic agent
Reglinide indication
- Type 2 diabetes for diet control, weight loss and exercise that cannot effectively control hyperglycemia. Combined with metformin has a synergistic effect on blood sugar control.
Clinical application of reglinide
- This product is usually taken within 15 minutes before a meal. The dose should be based on individual blood glucose conditions. The recommended starting dose is 0.5 mg. The maximum recommended single dose is 4 mg. Take this meal. However, the maximum daily dose should not exceed 16 mg.
Rigaglinide adverse reactions
- Hypoglycemia may occur, usually mildly. Abdominal pain, nausea are rare, diarrhea, vomiting and constipation and visual abnormalities, and liver abnormalities are very rare. Allergic reactions can occur allergic skin reactions, such as pruritus, rash, urticaria. Transaminase levels increased, most of them were mild and temporary.
Reginaline notes
- For debilitated and malnourished people, the dosage should be adjusted carefully. This product can affect the ability of the drug users to drive and operate machines.
Contraindications to reglinide
- Allergic to this product, type 1 diabetes, C peptide negative diabetes, diabetic ketoacidosis with or without coma, patients with severe liver function or renal insufficiency, pregnant or nursing women and children under 12 years old are contraindicated.
Reglinide drug interactions
- Monoamine oxidase inhibitors, non-selective beta blockers, ACE inhibitors, non-steroidal anti-inflammatory drugs, salicylates, octreotide, alcohol and anabolic hormones can enhance the hypoglycemic effect of this product. Beta blockers may mask symptoms of hypoglycemia.
- Note: The above content is only for introduction, the drug use must be carried out by a regular hospital under the guidance of a doctor.